Dr. Sébastien Fortin PhD is a regular researcher at the Centre de recherche du CHU de Québec-Laval University, Director of a pharmaceutical chemistry laboratory located at the Hôpital Saint-François d’Assise, and Assistant Professor at Laval University’s School of Pharmacy. He is author and co-author of 28 publications and co-inventor of 3 patents on the technologies that he develops. Dr. Fortin is the recipient of several awards and honors, including the Jean-François St-Denis Fellowship in Cancer Research from the Canadian Institutes of Health Research (CIHR) and the 2011 award for the best doctorate in cotutelle awarded by the Ministère des Relations internationales and the Consulat général de France à Québec. His research focuses on the design and development of new anticancer agents for use in personalized medicine.
Development of new drugs for personalized cancer chemotherapy
In Canada, cancer is the leading cause of death, followed only by cardiovascular diseases. Cancer is therefore a major public health problem. Despite recent medical breakthroughs, the ability to cure all cancer patients remains elusive. Consequently, we need to develop new treatments that will be more efficient, and more selective against cancer tumors, with the aim of improving the life expectancy and the quality of life of cancer patients. The aim of my research program is to design and prepare new anticancer agents exhibiting optimal biopharmaceutical and anticancer properties suitable for preclinical and clinical studies. My research themes are divided in two parts: 1) development of new inhibitors of DNA repair and replication mechanisms and 2) development of new inhibitors targeting cells deficient in homologous recombination. My research programs involve and focus on several interrelated and complementary disciplines, including molecular design and modeling, medicinal chemistry, cell biology, molecular pharmacology, and animal experimentation. The outcomes of these projects will contribute to the development of new, efficient and personalized anticancer treatments.
10, rue de l'Espinay
Canada G1L 3L5
Data not available
- Bouzriba, ChahrazedMaster student
- Camiré Bernier, ÉtienneInternetienne.firstname.lastname@example.org
- Chavez Alvarez, Atziri CorinMaster email@example.com
- Couturier, SoniaMaster firstname.lastname@example.org
- Marineau, PhilippeUndergraduate student
- Thibeault, DaphnéMaster email@example.com
- Zarifi Khosroshahi, MitraMaster studentHôpital Saint-François d'Assise+1 418-525-4444, extension firstname.lastname@example.org
10, rue de l'espinay
Canada G1L 3L5
Activation of Phenyl 4-(2-Oxo-3-alkylimidazolidin-1-yl)benzenesulfonates Prodrugs by CYP1A1 as New Antimitotics Targeting Breast Cancer Cells.Journal Article
J Med Chem, 60 (12), pp. 4963-4982, 2017, ISSN: 0022-2623.
Effectiveness of adjuvant carboplatin-based chemotherapy compared to cisplatin in non-small cell lung cancer.Journal Article
J Oncol Pharm Pract, pp. 1078155217724595, 2017, ISSN: 1078-1552.
Investigation of the DNA damage response to SFOM-0046, a new small-molecule drug inducing DNA double-strand breaks.Journal Article
Sci Rep, 6 , pp. 23302, 2016, ISSN: 2045-2322.
Synthesis and biological evaluation of novel N-phenyl ureidobenzenesulfonate derivatives as potential anticancer agents. Part 2. Modulation of the ring B.Journal Article
Eur J Med Chem, 103 , pp. 563-73, 2015, ISSN: 0223-5234.
Styryl-N-phenyl-N'-(2-chloroethyl)ureas and styrylphenylimidazolidin-2-ones as new potent microtubule-disrupting agents using combretastatin A-4 as model.Journal Article
Eur J Med Chem, 100 , pp. 34-43, 2015, ISSN: 0223-5234.
- Centre de recherche sur le cancer, Subvention, Institutionnel - BDR, BDR - Centres de recherche reconnus, from 1996-05-01 to 2023-04-30
- Centre hospitalier universitaire de Québec - CHU de Québec-Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
- Characterisation of the molecular structure and function of topoisomerase I using anticancer agents as molecular probes acting in a new allosteric binding-site, Subvention, Conseil de recherches en sciences naturelles et génie Canada, Subventions à la découverte SD (individuelles et d'équipe), from 2016-04-01 to 2021-03-31
Recently finished projects
- Establishment of a medical chemistry laboratory for the development of new anticancer drugs, Partenariat, Fondation Canadienne pour l'innovation (La), Fonds des leaders John-R.-Evans (FLJR), from 2016-12-01 to 2018-03-31
- Soutien à la recherche du Fonds de recherche de l'Hôpital Saint-François d'Assise, Subvention, Fondation de l'Université Laval, from 2016-05-01 to 2018-04-30
- Targeting the single-strand annealing pathway in synthetic lethal strategies for cancer treatment., Subvention, Fondation de l'Université Laval, from 2015-10-01 to 2017-09-30